THE LATEST ISSUE OF MABDESIGN’S IMMUNOWATCH, DEDICATED TO RADIOPHARMACEUTICALS, IS NOW AVAILABLE!
This issue takes a deep dive into one of the most dynamic areas of precision oncology. MabDesign’s Scientific and Business…
Other news
📰 Other categories:
-
-
NON-MUSCLE-INVASIVE BLADDER CANCER UNRESPONSIVE TO BCG: ALPHA THERAPY AS COMPARED TO CHEMOTHERAPY AND IMMUNOTHERAPY INCLUDING GENE THERAPY
Dr. Alexandra Paillard (Giteau) Dr. Jean-François Chatal Dr. Jacques Barbet Atonco SAS www.atonco-pharma.com Disclaimer This report has been compiled by…
-
TOWARDS NEW, MORE TARGETED WAYS OF TREATMENT
Bérénice Robert dans La Search trimestriel n°583 – Octobre-Décembre 2025
-
ATONCO AIMS TO REVOLUTIONIZE BLADDER CANCER TREATMENT
Les Echos – SME-Regions / InnovatorsSeptember 2025 In early 2026, Atonco plans to launch a clinical trial for its drug…
-
FRAMATOME INSTALLS FIRST RADIOISOTOPE PRODUCTION SITE IN NANTES
Les Echos – SME-Regions / InnovatorsBy Emmanuel Guimard – July 4, 2025 The nuclear energy specialist will invest €20 to…
-
TARGETED RADIONUCLIDE THERAPY: A MILLIMETER-PRECISE ORCHESTRATION
Magazine Pharmaceutiques n°328By Julie Wierzbicki – June-July 2025 From the processing of raw materials to patient administration, targeted radionuclide therapy…
-
FRAMATOME AND IBA TO PARTNER TO DEVELOP AN ASTATINE-211 CYCLOTRON NETWORK IN EUROPE AND THE USA
Framatome & IBA – Press ReleaseParis, France and Louvain-La-Neuve, Belgium – February 7, 2025 Framatome, an international leader in nuclear…